Sage Journals: Discover world-class research

Abstract

CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin converting enzyme (ACE), neutral endopeptidase (NEP), and endothelin (ET) converting enzyme-1 (ECE-1), with respective IC₅₀ values of 22, 2, and 55 nM. The aim of the present study was to establish the hemodynamic profile of Zucker diabetic fatty (Zdf)-Fatty rats, a high-fat diet gene-prone model developing spontaneous Type 2 diabetes (T2D) and the effects of CGS 35601. Male Zdf-Fatty (14 weeks, n = 17–23), Zdf-Lean (14 weeks, n = 8–10), and Wistar (14 weeks, n = 9–10) rats on distinct diets were implanted with a catheter in the left carotid and placed individually in a metabolic cage for 30 days. The hemodynamic profile and some metabolic biomarkers were assessed daily. After a 7-day stabilization period, the Zdf-Fatty rats were divided into two groups: Group 1, controls (n = 7–10) receiving vehicle-saline (250 μl/hr) and Group 2, (n = 10–13) receiving increasing doses of CGS 35601 (0.1, 1, and 5 mg/kg/day × 6 days each, intra-arterially) followed by a 5-day washout period. Mean arterial blood pressure (MABP) of young Zdf-Fatty rats was compared with age-matched Zdf-Lean and Wistar rats, which were found similar. MABP decreased by 5.9% (from baseline at 102 ± 5 to 96 ± 4 mmHg), 12.7% (to 89 ± 6 mmHg) and 21.6% (to 80 ± 4 mmHg), at 0.1, 1, and 5 mg/kg/day, respectively, in CGS 35601-treated Zdf-Fatty rats. Systolic and diastolic blood pressures were similarly reduced. The heart rate was not affected. Hyperglycemic status and insulin-resistance were not modulated by short-term treatment. CGS 35601 presented an excellent short-term safety profile. This novel molecule and class of VPI may be of interest for lowering vascular tone. Further long-term studies, once cardiovascular and renal complications have developed in this T2D rat model are warranted to define the efficacy of this class of VPI.

Get full access to this article

View all access options for this article.

References

Wassef L, Langham RG, Kelly DJ. Vasoactive renal factors and the progression of diabetic nephropathy. Curr Pharm Des 10:3373–3384, 2004.

Takahashi K, Ghatei MA, Lam HC, O’Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 33:306–310, 1990.

Bruno CM, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. Biol Regul Homeost Agents 16(2):114–117, 2002.

Harris AK, Hutchinson JR, Sachidanandam K, Johnson MH, Dorrance AM, Stepp DW, Fagan SC, Ergul A. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes 54:2638–2644, 2005.

Keynan S, Khamaisi M, Dahan R, Barnes K, Jackson CD, Turner AJ, Raz I. Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res 41:131–140, 2004.

Anstadt MP, Hutchinson J, Portik-Dobos V, Jafri F, Bannan M, Mawulawde K, Ergul A. Vascular endothelin converting enzyme-1 expression and activity is up-regulated in clinical diabetes. Ethn Dis 12:S3–S5–S9, 2002.

Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 42:48–54, 2003.

Sorokin A, Kohan DE. Physiology and pathology of endothelin-1 in renal mesangium. Am J Physiol Renal Physiol 285:F579–F589, 2003.

Feldman DL, Mogelesky TC, Chou M, Jeng AY. Attenuation of puromycin aminonucleoside-induced glomerular lesions in rats by CGS 26303, a dual neutral endopeptidase/endothelin-converting enzyme inhibitor. J Cardiovasc Pharmacol 36:S342–S345, 2000.

10.

Witte K, Reitenbach I, Stolpe K, Schilling L, Kirchengast M, Lemmer B. Effects of the endothelin A receptor antagonist darusentan on blood pressure and vascularcontractility in type 2 diabetic Goto-Kakizaki rats. J Cardiovasc Pharmacol 41:890–896, 2003.

11.

Hofman C, Gabai E, Peleg E, Munter K, Rosenthal T. Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat. Blood Press 14:114–119, 2005.

12.

Schafer S, Linz W, Vollert H, Biemer-Daub G, Rutten H, Bleich M, Busch AE. The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy. Diabetologia 47:98–103, 2004.

13.

Rossi GP, Cavallin M, Rizzoni D, Bova S, Mazzocchi G, Agabiti-Rosei E, Nussdorfer GG, Pessina AC. Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor. J Hypertens 20:1451–1459, 2002.

14.

Meier P, Maillard M, Burnier M. The future of angiotensin II inhibition in cardiovascular medicine. Curr Drug Targets Cardiovasc Haematol Disord 5:15–30, 2005.

15.

Taal MW, Nenov VD, Wong W, Satyal SR, Sakharova O, Choi JH, Troy JL, Brenner BM. Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol 12:2051–2059, 2001.

16.

Davis BJ, Johnston CI, Burrell LM, Burns WC, Kubota E, Cao Z, Cooper ME, Allen TJ. Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 46:961–971, 2003.

17.

Trapani AJ, Beil ME, Bruseo CW, Savage P, Firooznia F, Jeng AY. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme. J Cardiovasc Pharmacol 44:S211–S215, 2004.

18.

Nantel F, Daull P, Duta DN, Blouin A, Cayer J, Beaudoin M, Belleville K, Benrezzak O, Sirois P, Battistini B. The chronic, instrumented, unrestrained and conscious rat platform: application to animal models of diabetes. J Pharmacol Toxicol Methods 2005 Nov 6 [Epub ahead of print].

19.

Inguimbert N, Poras H, Teffo F, Beslot F, Selkti M, Tomas A, Scalbert E, Bennejean C, Renard P, Fournie-Zaluski MC, Roques BP. N-[2-(indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): in vitro and in vivo activities. Bioorg Med Chem Lett 12:2001–2005, 2002.

20.

Daull P, Benrezzak O, Arsenault D, Pheng LH, Blouin A, Cayer J, Beaudoin M, Belleville K, Sirois P, Nantel F, Jeng AY, Battistini B. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained and spontaneously hypertensive rats. Am J Hypertens 18: 1606–1613, 2005.

21.

Daull P, Blouin A, Belleville K, Beaudoin M, Arsenault D, Leonard H, Sirois P, Nantel F, Jeng AY, Battistini B. Triple VPI reduces high blood pressure in low-renin, high-salt Dahl-salt-sensitive rats. Exp Biol Med 231:830–834, 2006.

The Hemodynamic and Metabolic Profiles of Zucker Diabetic Fatty Rats Treated with a Single Molecule Triple Vasopeptidase Inhibitor,CGS 35601

Abstract

Get full access to this article

References